Compound. For the purposes of this Section 1.77, the definition of each of “Development Costs” and “Development” shall be deemed to apply to Option Compounds mutatis mutandis as it applies to Licensed Compounds and Licensed Products (i.e., substituting “Option Compounds” for “Licensed Compounds” or “Licensed Products”).
Appears in 3 contracts
Sources: Collaboration, License and Option Agreement (Acceleron Pharma Inc), Collaboration, License and Option Agreement (Acceleron Pharma Inc), Collaboration, License and Option Agreement (Acceleron Pharma Inc)